F. Porrot

This study characterizes SARS-CoV-2 variants XBB and BA.2.86/JN.1, finding they show increased fitness and antibody evasion while maintaining antiviral sensitivity.

This study characterizes the high fusogenicity and cytopathic effects of the SARS-CoV-2 B.1.640.1 variant, identifying mutations in the spike S2 domain responsible for these properties.

This study evaluates the neutralizing antibody resistance of SARS-CoV-2 Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to monoclonal antibodies and sera from vaccinated individuals.

This study identifies IRF8 as a regulator of CD20 expression and anti-CD20 antibody efficacy through CRISPR screening and functional validation in B cells.

This study examines the fusogenicity and neutralization sensitivity of the SARS-CoV-2 AY.4.2 sublineage compared to the Delta variant, finding similar spike function but reduced neutralization sensitivity to certain antibodies and vaccines.

This study shows that the Omicron variant of SARS-CoV-2 is resistant to most monoclonal antibodies and vaccine-induced antibodies, with reduced neutralization compared to Delta.

This study compares syncytia formation by SARS-CoV-2 Alpha, Beta, and Delta variants to D614G, finding enhanced fusogenicity and differential effects of mutations on ACE2 binding and antibody escape.

This study shows that the SARS-CoV-2 B.1.617.2 variant is less sensitive to monoclonal antibodies and sera from convalescent and vaccinated individuals compared to other variants.

The paper identifies DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen, showing it limits viral replication independently of SUMOylation.

This study assesses the neutralization sensitivity of SARS-CoV-2 B.1.1.7 and B.1.351 variants compared to D614G using sera and nasal swabs, finding reduced efficacy against B.1.351 in some convalescent and vaccinated individuals.

This study shows SARS-CoV-2 infected cells form syncytia via Spike protein-mediated fusion, regulated by IFITMs and TMPRSS2.